Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding

https://escholarship.org/uc/item/9gt4f941

Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 22(2)

1936-900X

Rech, Megan A.
Masic, Dalila
Hammond, Drayton A.

2021

10.5811/westjem.2020.11.47931

Copyright 2021 by the author(s). This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/
**Original Research**

**Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding**

Megan A. Rech, PharmD, MS*†  
Dalila Masic, PharmD*  
Drayton A. Hammond, PharmD, MBA, MSc‡§  

*Loyola University Medical Center, Department of Pharmacy, Maywood, Illinois  
†Stritch School of Medicine, Loyola University Chicago, Department of Emergency Medicine, Maywood, Illinois  
‡Rush University Medical Center, Department of Pharmacy, Chicago, Illinois  
§Rush Medical College, Department of Internal Medicine, Chicago, Illinois

**Section Editor:** Mark I. Langdorf, MD, MHPE  
Submission history: Submitted April 28, 2020; Revision received October 19, 2020; Accepted November 11, 2020  
Electronically published February 26, 2021  
Full text available through open access at http://escholarship.org/uc/uciem_westjem  
DOI: 10.5811/westjem.2020.11.47931

**INTRODUCTION**

Factor Xa (fXa) inhibitors (eg, apixaban and rivaroxaban) are a class of direct oral anticoagulants that are widely used for a variety of indications, including venous thromboembolism and atrial fibrillation.¹ ² Use of these agents has steadily increased over the last decade. This is in part because of their ease of use compared to warfarin, which requires frequent laboratory monitoring and dietary modifications and which interacts with numerous medications due to metabolism by a number cytochrome P450 enzymes, posing safety risks. Compared to warfarin, fXa inhibitors appear to have a lower rate of intracerebral hemorrhage, with annual rates of 0.1-0.2% compared to 0.3-0.6% of patients on warfarin.³ ⁴ However, whereas four-factor prothrombin complex concentrate (4F-PCC) and vitamin K are generally considered the standard of care for reversal of life-threatening bleeding secondary to warfarin (due to warfarin’s availability it has been more extensively studied), reversal of fXa inhibitors in this setting remains controversial due to a lack of high-quality evidence.⁵ ⁸

Several national and international guidelines endorse...
the use of 4F-PCC for the reversal of fXa inhibitors; however, its exact place in therapy overall and in relation to andexanet alfa is discordant among these guidelines.\(^1\)\(^2\)\(^9\)\(^11\) Although andexanet alfa was specifically designed for reversal of fXa inhibitors, it has not seen widespread use because many institutions have not approved it due to a lack of robust evidence, including a comparator group in the available studies, questionable risk of thromboembolism, and the poor value proposition and cost-effectiveness of the therapy.\(^1\)\(^2\)\(^3\) The range of recommendations for its use include the following: 4F-PCC as a first-line therapy for fXa inhibitor reversal\(^1\)\(^2\)\(^10\)\(^11\); 4F-PCC as a first-line therapy as an alternative to discontinuation of fXa inhibitors alone (eg, meaning that perhaps no reversal agent would be appropriate);\(^2\) and 4F-PCC as a second-line agent after andexanet alfa.\(^9\) These differences stem from the relatively poor quality of evidence for both agents and include a degree of expert opinions. The limited data available are comprised of small, single-center studies that lack a comparator group.\(^14\)\(^20\) The purpose of this study was to determine the hemostatic efficacy of 4F-PCC for the reversal of fXa inhibitor-related, life-threatening bleeding compared to 4F-PCC for warfarin-related life-threatening bleeding.

**METHODS**

This was a multicenter, retrospective cohort study conducted at two urban, academic medical centers between January 1, 2014–December 31, 2019. The study included patients who presented to the emergency department (ED) with a life-threatening bleed necessitating anticoagulation reversal with 4F-PCC. To be included in the study, there had to be confirmation of warfarin or fXa inhibitor use (ie, apixaban, betrixaban, edoxaban, or rivaroxaban) prior to presentation, which necessitated rapid reversal for life-threatening bleeding. Patients were excluded if any of the following criteria were present: age less than 18 years; receipt of 4F-PCC outside of the ED setting or at an outside hospital prior to arrival; receipt of 4F-PCC for any indication aside from life-threatening bleeding; concurrent factor VII use; history of heparin-induced thrombocytopenia; or known disseminated intravascular coagulation. Both institutions’ institutional review boards approved the research protocol.

Life-threatening bleeding was treated according to institutional protocols at the discretion of the treating services. Both institutions preferentially used 4F-PCC for the reversal of life-threatening bleeding in patients on fXa inhibitors or warfarin during the study period. Institutional protocols at both sites recommended dosing of 4F-PCC at 50 factor IX units per kilogram for fXa inhibitor reversal and between 25-50 IX units/kg for warfarin reversal based on a pre-treatment international normalized ratio (INR) value. The primary endpoint was achievement of hemostatic efficacy after 4F-PCC administration as defined by the Scientific and Standardization Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Hemostasis Scientific (ISTH) for the assessment of the effectiveness of major bleeding management.\(^2\)\(^1\)\(^\text{Vol} \text{22, No. 2: March 2021}\)

Hemostasis for intracranial hemorrhage was defined as stabilization at or less than a 35% increase in hematoma volume on imaging. All patients had repeat imaging based on treatment protocols. Hemostasis for visible bleeding was defined as cessation of visible bleeding within four hours of 4F-PCC administration. Hemostasis for non-visible bleeding was defined as stable hemoglobin at 48 hours post-4F-PCC administration. Hemostasis was assessed by one of the study investigators upon data collection. Secondary endpoints were the number of transfusions of packed red blood cells, platelet, and fresh frozen plasma, discharge disposition, intensive care unit length of stay, hospital length of stay, and hospital and 30-day mortality. Safety endpoints were any adverse event during hospitalization (ie, deep vein thrombosis [DVT], pulmonary embolism, ischemic stroke, arterial thrombus, myocardial infarction, hypersensitivity reaction, transfusion-related acute lung injury, and transfusion-associated circulatory overload).

**Statistical Analyses**

Baseline and clinical characteristics were characterized...
using descriptive statistics. We assessed normality of continuous variables using the Shapiro-Wilk test. Normally distributed continuous variables were analyzed using Student’s t-test. We used the Mann-Whitney U test to analyze on-parametric data. A chi-square or Fisher’s exact test was used to compare categorical variables, as appropriate. We analyzed data using STATA version 15 (StataCorp, College Station, TX).

RESULTS

Of the 525 patients who had an order for 4F-PCC during the study period, 148 patients met the criteria for inclusion (n = 48 fXa inhibitor group; n = 100 warfarin group; Figure 1). The most common reasons for exclusion were receipt of 4F-PCC outside of the ED (n = 270) and use for non-life-threatening bleeding (n = 98).

Baseline demographics were similar between groups (Table 1). Patients in the fXa inhibitor group were older (78.4 years fXa inhibitor group vs 73.9 years warfarin group, \(P = 0.03\)), while patients in the warfarin group had a higher incidence of end-stage renal disease (2.1% vs 18%, \(P < 0.01\)). Apixaban (52.1%) and rivaroxaban (45.8%) were the most commonly used fXa inhibitors, with only one patient (2.1%) on edoxaban. Most patients in both groups were on an oral anticoagulant for atrial fibrillation-associated stroke prevention. Anticoagulation for mechanical mitral valve only occurred in the warfarin group (0% vs 19%, \(P < 0.01\)). Concomitant antiplatelet use was similar between groups, with aspirin being the most common agent (29.7% vs 26%, \(P = 0.69\)), followed by clopidogrel (16.7% vs 21%, \(P = 0.53\)). Only two patients, both in the warfarin group, were on dual antiplatelet therapy.

The most common indication for 4F-PCC in both groups was intracranial bleeding, which occurred more frequently in the warfarin group (52.1% vs 67%, \(P = 0.02\); Table 2). Visible bleeding was more common in the fXa inhibitor group (31.3% vs 15%, \(P = 0.02\)), while non-visible bleeding was similar between groups (16.7% vs 17%). Four-factor prothrombin complex concentrate was administered more often during weekdays and day shifts in both groups. Baseline laboratory parameters were similar between groups, although warfarin patients had higher INR (1.2 vs 3.2, \(P < 0.01\)). Patients in the fXa-group received a higher total and weight-based dose of 4F-PCC than the warfarin group. Most doses in both groups were deemed appropriate according to institutional guidelines. There was little difference between groups in time to 4F-PCC initiation (106.5 minutes vs 140 minutes, \(P = 0.12\)).

The primary endpoint of effective hemostasis was similar between groups (79.2% vs 85%, \(P = 0.38\); Table 3). This was consistent across all types of bleeding with no differences observed in intracranial bleeding, visible bleeding, or non-visible bleeding hemostasis. No patients received additional hemostatic agents or coagulation factors at 48 hours after 4F-PCC. All efficacy and safety secondary endpoints were similar between groups. Only three adverse effects occurred overall. One patient in each group developed DVT and one ischemic stroke occurred in the warfarin group.

DISCUSSION

This multicenter, retrospective cohort study demonstrated that using 4F-PCC for treatment of life-threatening bleeding produced effective hemostasis in patients on both fXa inhibitors and warfarin. Hemostasis was high overall, occurring in 79.2% of the fXa inhibitor group and 85%
of the warfarin group. Hemostasis rates were consistent with previously reported literature.\textsuperscript{8,15,19,20} The addition of a comparator group (eg, warfarin) in our study allowed for a frame of reference to be available, unlike prior studies that analyzed 4F-PCC use in fXa inhibitor-induced bleeding. This is important as 4F-PCC is generally considered the treatment of choice for warfarin-related bleeding, but guideline recommendations are more heterogeneous when it comes to

### Table 1. Baseline characteristics of patients treated for life-threatening bleeding.

| Characteristic                                      | fXa-Inhibitors (n=48) | Warfarin (n=100) | P-value |
|------------------------------------------------------|-----------------------|------------------|---------|
| Male gender, n (%)                                   | 28 (52.1)             | 64 (64)          | 0.17    |
| Age at bleed (years), median (IQR)                   | 78.4 (68.9 – 83.9)    | 73.9 (62.6 – 82.3) | 0.03    |
| BMI (kg/m2), median (IQR)                            | 26.8 (24 – 31.8)      | 28.6 (28.6 – 32.3) | 0.24    |
| Race, n (%)                                          |                       |                  | 0.67    |
| Black                                                | 9 (18.8)              | 20 (20)          |         |
| White                                                | 31 (64.6)             | 55 (55)          | 0.11    |
| Hispanic                                             | 3 (6.3)               | 9 (9)            | 0.11    |
| Other                                                | 5 (10.4)              | 16 (16)          | <0.01   |
| Comorbidities                                        |                       |                  | 0.19    |
| Atrial fibrillation                                  | 40 (83.3)             | 70 (70)          | 0.53    |
| Cancer                                               | 13 (27.1)             | 16 (16)          | 0.24    |
| End-stage renal disease                              | 1 (2.1)               | 18 (18)          | 0.34    |
| Heart failure                                        | 13 (27.1)             | 38 (38)          |         |
| Venous thromboembolism                               | 8 (16.7)              | 21 (21)          |         |
| SOFA score on admission, median (IQR)                | 3 (2 – 5)             | 2 (1 – 5)        |         |
| GCS score on admission, median (IQR)                 | 14 (10 – 15)          | 15 (11 – 15)     |         |
| Anticoagulation, n (%)                               |                       |                  |         |
| Warfarin                                             | --                    | 100 (100)        |         |
| Rivaroxaban                                          | 22 (45.8)             | --               |         |
| Apixaban                                             | 25 (52.1)             | --               |         |
| Edoxaban                                             | 1 (2.1)               | --               |         |
| Indication for anticoagulation, n (%)                |                       |                  |         |
| Atrial fibrillation                                  | 39 (81.3)             | 68 (68)          | 0.12    |
| Cancer-related venous thromboembolism                | 1 (2.1)               | 1 (1)            | 0.59    |
| Deep venous thrombosis                               | 8 (16.7)              | 10 (10)          | 0.25    |
| History of venous thromboembolism                    | 2 (4.2)               | 7 (7)            | 0.50    |
| Mechanical mitral valve                              | 0 (0)                 | 19 (19)          | <0.01   |
| Pulmonary embolism                                   | 4 (8.3)               | 8 (8)            | 0.95    |
| Ventricular assist device                            | 0 (0)                 | 4 (4)            | 0.16    |
| Concomitant antiplatelet, n (%)                      |                       |                  |         |
| Aspirin                                              | 11 (29.7)             | 26 (26)          | 0.69    |
| Clopidogrel                                          | 8 (16.7)              | 21 (21)          | 0.53    |
| Prasugrel                                            | 2 (4.2)               | 1 (1)            | 0.20    |
| Dual antiplatelet therapy                            | 0 (0)                 | 2 (2)            | 0.33    |
| Baseline laboratory parameters, median (IQR)         |                       |                  |         |
| INR                                                  | 1.2 (1.1 – 1.9)       | 3.2 (2.4 – 6.3)  | <0.01   |
| Hemoglobin, g/dL                                     | 11.3 (8.2 – 13.2)     | 11.5 (9.8 – 13.2) | 0.53    |
| Platelets, x10\(^9\)/L                              | 219 (161 – 257)       | 212 (172 – 257)  | 0.82    |

\(\text{fXa}\), factor Xa; \(\text{IQR}\), interquartile range; \(\text{kg}\), kilogram; \(\text{m2}\), meter squared; \(\text{BMI}\), body mass index; \(\text{SOFA}\), sequential organ failure assessment; \(\text{GCS}\), Glasgow Coma Scale; \(\text{INR}\), international normalized ratio; \(\text{g}\), gram; \(\text{dL}\), deciliter; \(\text{L}\), liter.
recommending 4F-PCC for fXa-inhibitor-related bleeding due to a paucity of evidence guiding treatment decisions.\textsuperscript{1,2,9,11}

Previous studies of fXa inhibitor-related bleeding reversal have observed similar efficacy rates as this study (range: 72.4-85\%), although most describe single-center efforts with low patient enrollment rates and no comparator group.\textsuperscript{5,15,19,20} The largest retrospective cohort study to date included 663 patients with intracranial hemorrhage, of whom 433 were evaluated for hemostatic efficacy.\textsuperscript{8}

Within this patient cohort, efficacy was deemed excellent or good (according to hematoma expansion ≤20% or 20.1-35\%, respectively) in 81.8\% of patients. A prospective observational study of 66 patients receiving a fixed dose of 2000 IX units did a post hoc analysis for effective hemostatic according to ISTH criteria and found 68\% of patients achieved effectiveness.\textsuperscript{15} A meta-analysis including 10 case series of 340 patients found that only two studies used the ISTH criteria to define hemostasis.\textsuperscript{22} In these studies, the effective management of major bleeding was achieved in 69\% of patients (95\% confidence interval [CI], 61-76\%). There was a low rate of thromboembolic events within 30 days (3\% [95\% CI, 0-6\%]). None of the included studies had a comparator arm. Our study enhances the current literature with the addition of a comparator group, which provides a frame of reference for clinicians to consider when determining oral anticoagulant choice and potential outcomes if a life-threatening bleed occurs.

If a reversal agent predisposes patients to developing a thrombotic event following use, its utility may be greatly diminished. Thus, careful monitoring for adverse effects is important. In this study, safety outcomes occurred very infrequently and were similar between groups. One patient experienced a DVT in the fXa inhibitor group, compared to one DVT and one stroke in the warfarin group. The fXa inhibitor patient required subsequent anticoagulation and did not experience any further adverse effects or mortality. Other studies have reported similar adverse effects.\textsuperscript{8,15,19,20} A single-center, retrospective cohort study of 4F-PCC used for either reversal of fXa inhibitor induced life-threatening bleeding or need for emergent procedure also found only one adverse effect, a DVT.\textsuperscript{14} A large, multicenter study found thrombotic events in 3.8\% of patients.\textsuperscript{8} Thus, according to this study and previous literature, it appears that 4F-PCC is a relatively safe intervention in the treatment of fXa inhibitor- and warfarin-related bleeding.

**LIMITATIONS**

This study has several limitations that warrant consideration. First, despite being one of the largest studies of fXa inhibitor-induced bleeding reversed with 4F-PCC, it is a retrospective cohort study of a relatively limited number of patients, with only 48 patients in the fXa inhibitor group. We attempted to improve upon previous literature by including two academic centers and comparing

| Characteristic | fXa-Inhibitors (n=48) | Warfarin (n=100) | P-value |
|---------------|----------------------|------------------|---------|
| Type of Bleed, n (%) |                       |                  |         |
| Intracranial bleeding | 25 (52.1) | 67 (67) | 0.02 |
| Visible bleeding | 15 (31.3) | 15 (15) |         |
| Non-visible bleeding | 8 (16.7) | 17 (17) |         |
| 4F-PCC day of the week, n (%) |               |                  | 0.65 |
| Weekday (Monday – Friday) | 38 (79.2) | 75 (75) |         |
| Weekend (Saturday, Sunday) | 10 (20.8) | 25 (25) |         |
| 4F-PCC shift, n (%) |                       |                  | 0.65 |
| Day (0701 to 1900) | 38 (79.2) | 76 (76) |         |
| Evening (1901 to 0700) | 10 (20.8) | 24 (24) |         |
| Laboratory parameters, median (IQR) |               |                  |         |
| INR after 4F-PCC | 1.2 (1.1 – 1.3) | 1.2 (1.1 – 1.4) | 0.65 |
| Hemoglobin, g/dL, 48 hours | 9.9 (8.9 – 12) | 10.2 (8.7 – 12.2) | 0.93 |
| Platelets, x10\(^9\)/L, 48 hours | 185 (141 – 226) | 186 (144 – 216) | 0.68 |
| 4F-PCC dose, units, median (IQR) | 3932 (3212 – 4516) | 2265 (1740 – 3136) | <0.01 |
| 4F-PCC dose, units/kg, median (IQR) | 49.9 (47.3 – 52.4) | 27.5 (24.4 – 35.3) | <0.01 |
| Time to 4F-PCC, minutes, median (IQR) | 106.5 (64 – 216) | 140 (77 – 240) | 0.12 |
| Appropriate 4F-PCC dose, n (%) | 43 (89.6) | 84 (84) | 0.35 |

\(\text{fXa, factor Xa; 4F-PCC, four-factor prothrombin complex concentrate; IQR, interquartile range; g, gram; dL, deciliter; L, liter; INR, international normalized ratio.}\)
Four-factor PCC efficacy and safety to warfarin, where it has been established as the standard of care for reversal in the setting of life-threatening bleeding. However, this may have introduced bias as FXa inhibitors likely cause less severe bleeding than warfarin. Second, in an attempt to have the most complete data possible in terms of timing and documentation, we excluded the 270 patients experiencing life-threatening bleeding outside of the ED, which may have limited our external validity. Additionally, a previous study found that time to intervention could potentially affect outcomes. While we collected data from ED arrival to administration of 4F-PCC, the time of last dose of anticoagulant was not readily available. Finally, thrombotic adverse effects could have occurred after discharge and may have been missed due to a relatively short follow-up period, especially if patients reported to an outside hospital that was not connected with our electronic health record.

**CONCLUSION**

This multicenter, retrospective cohort study demonstrated that using 4F-PCC for treatment of life-threatening bleeding produced effective hemostasis in patients on FXa inhibitors and warfarin. Although larger, prospective comparative studies are needed to determine the efficacy of 4F-PCC as a reversal agent for FXa inhibitor-related, life-threatening bleeding, this study adds to the existing literature supporting use of 4F-PCC for this indication based on the hemostatic efficacy and safety of this intervention.

| Table 3. Hemostatic efficacy. | fXa-Inhibitors (n=48) | Warfarin (n=100) | P-value |
|-------------------------------|----------------------|-----------------|---------|
| **Primary endpoint**          |                      |                 |         |
| Effective hemostasis, n (%)   | 38 (79.2)            | 85 (85)         | 0.38    |
| **Hemostasis by type of bleed** |                      |                 |         |
| Intracranial bleeding hemostasis, n (%) | n = 25             | n = 25          |         |
| Hematoma volume stable or increased by <35% compared to baseline | 19 (76)            | 59 (86.8)      | 0.21    |
| Deterioration in GCS at 24 hours | 2 (8)               | 6 (8.8)         | 0.90    |
| Need for further hemostatic agents or coagulation factors at 48 hours | 4 (16)              | 25 (36.8)       | 0.06    |
| Visible bleeding hemostasis, n (%) | n = 15              | n = 15          |         |
| Cessation of visible bleeding within 4 hours of 4F-PCC administration | 14 (93.3)           | 15 (100)        | 0.29    |
| Need for further hemostatic agents or coagulation factors at 48 hours | 12 (80)             | 12 (80)         | >0.99   |
| Non-visible bleeding hemostasis, n (%) | n = 8               | n = 17          |         |
| Stable hemoglobin at 24 hours after 4F-PCC | 8 (100)             | 17 (100)        | >0.99   |
| Need for further hemostatic agents or coagulation factors at 48 hours | 4 (50)              | 12 (75)         | 0.32    |
| **Secondary outcomes**        |                      |                 |         |
| Mortality, n (%)              |                      |                 |         |
| Hospital                      | 8 (16.7)             | 14 (14)         | 0.69    |
| 30-day                        | 9 (18.8)             | 17 (17)         | 0.81    |
| Length of stay, median (IQR)  |                      |                 |         |
| Intensive care unit           | 2 (1 – 7)            | 3 (2 – 7)       | 0.31    |
| Hospital                      | 6 (4 – 10)           | 7 (4 – 13)      |         |
| Adverse event during hospitalization, n (%) | 1 (2.1)             | 2 (2)           | 0.97    |
| Packed red blood cells within 24 hours of 4F-PCC, median (IQR) | 17 (35.4)           | 24 (24)        | 0.15    |
| Platelet transfusions within 24 hours of 4F-PCC, median (IQR) | 4 (8.3)              | 21 (21)         | 0.05    |
| Fresh frozen plasma within 24 hours of 4F-PCC, median (IQR) | 6 (12.5)             | 23 (23)         | 0.13    |

FXa, factor Xa; GCS, Glasgow Coma Scale; 4F-PCC, four-factor prothrombin complex concentrate; IQR, interquartile range.
Four-factor PCC Reversal of Factor Xa Inhibitors versus Warfarin

REFERENCES

1. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121-201.

2. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-91.

3. Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonist for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304-12.

4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.

5. Mujer MTP, Rai MP, Atti V, et al. An update on the reversal of non-vitamin K antagonist oral anticoagulants. Adv Hematol. 2020;2020:7636104.

6. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIb study. Circulation. 2013;128(11):1234-43.

7. Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077-87.

8. Panos NG, Cook AM, John S, et al. Factor Xa inhibitor-related intracranial hemorrhage (FIX-ICH): results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation. 2020;141(21):1681-9.

9. Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med. 2020;76(4):470-85.

10. Rossaint R, Bouillon B, Cerny V, et al. The European Guideline on Management of Major Bleeding and Coagulopathy Following Trauma, Fourth edition. Crit Care. 2016;20:100.

11. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(24):3042-67.

12. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-35.

13. Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-41.

14. Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care. 2018;6(1):1-6.

15. Schulman S, Gross PL, Ritchie B, et al. Prothrombin complex concentrate for major bleeding on factor Xa Inhibitors: a prospective cohort study. Thromb Haemost. 2018;118(5):842-51.

16. Dybdahl D, Walliser G, Chance Spalding M, et al. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage. Am J Emerg Med. 2019;37(10):1907-11.

17. Grandhi R, Newman WC, Zhang X, et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 2015;84(6):1956-61.

18. Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrates administration and hematoma enlargement in NOAC-related intracranial hemorrhage. Ann Neurol. 2018;83(1):86-96.

19. Sheikh-Taha M. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Intern Emerg Med. 2019;14(2):265-9.

20. Smith MN, Deloney L, Carter C, et al. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis. 2019;48(2):250-5.

21. Khorsand N, Majeed A, Sarode R, et al. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(1):211-4.

22. Piran S, Khatib R, Schulman S, et al. Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv. 2019;3(2):158-67.

23. Eikelboom J, Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Med. 2016;129(11):S33-40.

24. Masic D, Hidalgo DC, Kuhrau S, et al. Pharmacist presence decreases time to prothrombin complex concentrate in emergency department patients with life-threatening bleeding and urgent procedures. J Emerg Med. 2019;57(5):620-8.